In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1× · see citing works

Drug Metabolism and Variability among Patients in Drug Response

Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185 · see citing works

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Williams, J. A., Hyland, R., Jones, B., Smith, D. A., Hurst, S. I., Goosen, T. C., Peterkin, V. C., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 929 · see citing works

THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870 · see citing works

Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily

Mackenzie, P. I., Walter Bock, K., Burchell, B., Guillemette, C., Ikushiro, S.-I., Iyanagi, T., Miners, J. O., Owens, I. S., & Nebert, D. W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000173483.13689.56 · Cited by 821 · see citing works

Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism

Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 790 · see citing works

Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P. G., Wolff, T., & Waxman, D. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89213-x · Cited by 724 · see citing works

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*

Thummel, K. E., O’Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 615 · see citing works

Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.

Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., & Guzelian, P. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113156 · Cited by 480 · see citing works

Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism

Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J. K., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 450 · see citing works

Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide

Osborne, R. H., Joel, S., Trew, D., & Slevin, M. L. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.2 · Cited by 444 · see citing works

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial

STOLTZ, M., REYNOLDS, D., ELKINS, L., SALAZAR, D., & Weir, S. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90252-x · Cited by 440 · see citing works

Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

Ohno, S., & Nakajin, S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023598 · Cited by 428 · see citing works

First-pass metabolism of cyclosporin by the gut

Kolars, J. C., Watkins, P. B., Merion, R. M., & Awni, W. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92302-i · Cited by 423 · see citing works

In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model

Houston, J. B., & Kenworthy, K. E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15358-5 · Cited by 391 · see citing works

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism* †

Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375 · see citing works

Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*

Ducharme, M. P., Warbasse, L. H., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90032-2 · Cited by 349 · see citing works

Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin

Boxenbaum, H. G. (1980) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065191 · Cited by 348 · see citing works

In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin

Fisher, M. B., Campanale, K. M., Ackermann, B. L., VandenBranden, M. R., & Wrighton, S. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15100-8 · Cited by 343 · see citing works

Characterization of Human Small Intestinal Cytochromes P-450

Zhang, Q., Dunbar, D. A., Ostrowska, A., Zeisloft, S., Yang, J., & Kaminsky, L. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15229-4 · Cited by 343 · see citing works

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

Hébert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.171 · Cited by 337 · see citing works

First-pass metabolism of midazolam by the human intestine*

Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 323 · see citing works

Tissue Distribution of mRNA Expression of Human Cytochrome P450 Isoforms Assessedby High-Sensitivity Real-Time Reverse Transcription PCR

Nishimura, M., YAGUTI, H., YOSHITSUGU, H., Naito, S., & Satoh, T. (2003) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.123.369 · Cited by 313 · see citing works

Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines

Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., & Yokoi, T. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021428 · Cited by 287 · see citing works

Cytochromes P450 and experimental models of drug metabolism

Zuber, R., Anzenbacherová, E., & Anzenbacher, P. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00186.x · Cited by 284 · see citing works

Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin

Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. F. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283 · see citing works

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hébert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 279 · see citing works

Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus

Gong, Q.-H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., Kubota, S., Carvalho, S., Pennington, M. W., Owens, I. S., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00011 · Cited by 271 · see citing works

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*

Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q. A., Dressler, D. E., Lee, J. W., Roberts, J. P., & Hébert, M. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90150-8 · Cited by 269 · see citing works

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

Tsunoda, S. M., VELEZ, R., VONMOLTKE, L., & Greenblatt, D. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70009-3 · Cited by 257 · see citing works

Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M. F., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 256 · see citing works

Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine

Strassburg, C. P., Kneip, S., Topp, J., Obermayer–Straub, P., Barut, A., Tukey, R. H., & Manns, M. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002180200 · Cited by 249 · see citing works

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential

Miners, J., Mackenzie, P., & Knights, K. (2010) · Drug metabolism reviews (Softcover ed.) · doi:10.3109/03602530903210716 · Cited by 249 · see citing works

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M. M., van Waterschoot, R. A. B., Smit, J. W., Song, J.-Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W. A., Rosing, H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33435 · Cited by 235 · see citing works

Pharmacokinetics and Modeling of Quercetin and Metabolites

Chen, X., Yin, O. Q. P., Zuo, Z., & Chow, M. S. S. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4584-1 · Cited by 233 · see citing works

THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTS

Bernard, O., & Guillemette, C. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.775 · Cited by 229 · see citing works

In Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance

Soars, M. G., Burchell, B., & Riley, R. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 229 · see citing works

Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen

Crespy, V., Morand, C., Manach, C., Besson, C., Demigné, C., & Rémésy, C. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.277.1.g120 · Cited by 215 · see citing works

Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., & Vyas, K. P. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07382-9 · Cited by 209 · see citing works

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

Górski, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00187-5 · Cited by 207 · see citing works

Characterization of Raloxifene Glucuronidation in Vitro: Contribution of Intestinal Metabolism to Presystemic Clearance

Kemp, D. C., Fan, P. W., & Stevens, J. C. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.694 · Cited by 193 · see citing works

Tissue mRNA Expression of the Rat UDP-Glucuronosyltransferase Gene Family

Shelby, M. K., Cherrington, N. J., Vansell, N. R., & Klaassen, C. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.326 · Cited by 187 · see citing works

The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

Gupta, M., Kovar, A., & Meibohm, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276847 · Cited by 181 · see citing works

The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.

Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., & Heidemann, H. T. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08415-6 · Cited by 178 · see citing works

The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites

Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A., & Remesy, C. (2006) · European Journal of Nutrition · doi:10.1007/s00394-005-0568-5 · Cited by 164 · cited 1× · see citing works

First-pass effect of morphine in rats.

Iwamoto, K., & Klaassen, C. D. (1977) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30761-5 · Cited by 160 · see citing works

Natural polyphenol disposition via coupled metabolic pathways

Liu, Z., & Hu, M. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.3.389 · Cited by 158 · see citing works

Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

Galetin, A., & Houston, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106013 · Cited by 155 · see citing works

Metabolism and Transport of the Macrolide Immunosuppressant Sirolimus in the Small Intestine

Lampen, A., Zhang, Y., Hackbarth, I., Benet, L. Z., Sewing, K.-F., & Christians, U. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37526-3 · Cited by 150 · see citing works

Metabolism and Transport of the Citrus Flavonoid Hesperetin in Caco-2 Cell Monolayers

Brand, W., van der Wel, P. A. I., Rein, M. J., Barron, D., Williamson, G., van BLADEREN, P. J., & Rietjens, I. M. C. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019943 · Cited by 146 · see citing works

IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)

Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S. K., Alton, K. B., Patrick, J. E., & Zbáida, S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.314 · Cited by 143 · see citing works

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

Cubitt, H. E., Houston, J., & Galetin, A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9823-9 · Cited by 134 · see citing works

Role of Intestinal First-Pass Metabolism of Baicalein in its Absorption Process

Li, Z., Lin, G., Chang, Q., & Zuo, Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-5303-7 · Cited by 133 · see citing works

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank

Fisher, M. B., VandenBranden, M. R., Findlay, K. A. B., Burchell, B., Thummel, K. E., Hall, S. D., & Wrighton, S. A. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00007 · Cited by 133 · see citing works

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects

Takanaga, H., OHNISHI, A., MURAKAMI, H., Matsuo, H., Higuchi, S., Urae, A., Irie, S., Furuie, H., 松隈京子, & KIMURA, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104215 · Cited by 131 · see citing works

Dose-Independent Pharmacokinetics of Metformin in Rats: Hepatic and Gastrointestinal First-Pass Effects

Choi, Y. H., Kim, S. G., & Lee, M. G. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20744 · Cited by 129 · see citing works

Involvement of UDP-Glucuronosyltransferases in the Extensive Liver and Intestinal First-Pass Metabolism of Flavonoid Baicalein

Li, Z., Lin, G., & Zuo, Z. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9126-y · Cited by 123 · see citing works

Comparative human pharmacokinetics and metabolism of single‐dose oral and intravenous sildenafil

Muirhead, G. J., Rance, D. J., Walker, D. K., & Wastall, P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.06-5251.2001.00028.x · Cited by 120 · see citing works

Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.

Mistry, M., & Houston, J. B. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06808-4 · Cited by 120 · see citing works

Absorption and Intestinal Metabolism of SDZ-RAD and Rapamycin in Rats

Crowe, A. P., Bruelisauer, A., Duerr, L., Guntz, P., & Lemaire, M. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15260-9 · Cited by 120 · see citing works

Regulation of UDP glucuronosyltransferases in the gastrointestinal tract

Gregory, P. A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.008 · Cited by 115 · see citing works

Clinical implications ofCYP3Apolymorphisms

Wojnowski, L., & Kamdem, L. K. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.2.171 · Cited by 114 · see citing works

Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam

Granvil, C. P., Yu, A., Elizondo, G., Akiyama, T. E., Cheung, C., Feigenbaum, L., Krausz, K. W., & Gonzalez, F. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.548 · Cited by 106 · see citing works

Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10

Mizuma, T. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.044 · Cited by 106 · see citing works

Isolation and Characterization of a New Major Intestinal CYP3A Form, CYP3A62, in the Rat

Matsubara, T., Kim, H. J., Miyata, M., Shimada, M., Nagata, K., & Yamazoe, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061671 · Cited by 104 · see citing works

In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat

Kotegawa, T., Laurijssens, B. E., Moltke, L. L., Cotreau, M. M., Perloff, M. D., Venkatakrishnan, K., Warrington, J. S., Granda, B. W., Harmatz, J. S., & Greenblatt, D. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035972 · Cited by 104 · see citing works

COMPARISON OF MOUSE AND RAT CYTOCHROME P450-MEDIATED METABOLISM IN LIVER AND INTESTINE

Martignoni, M., Groothuis, G., & de Kanter, R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009035 · Cited by 101 · see citing works

Characterization of rat small intestinal cytochrome P450 composition and inducibility.

Zhang, Q. Y., Wikoff, J., Dunbar, D. A., & Kaminsky, L. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07350-7 · Cited by 101 · see citing works

The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes

Bowalgaha, K., & Miners, J. O. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01487.x · Cited by 100 · see citing works

SPECIES- AND DISPOSITION MODEL-DEPENDENT METABOLISM OF RALOXIFENE IN GUT AND LIVER: ROLE OF UGT1A10

Jeong, E. J., Liu, Y., Lin, H., & Hu, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001883 · Cited by 100 · see citing works

Innovative Methods to Study Human Intestinal Drug Metabolism in Vitro: Precision-Cut Slices Compared with Ussing Chamber Preparations

van de Kerkhof, E. G., Ungell, A.-L. B., Sjöberg, Å. K., de Jager, M. H., Hilgendorf, C., de Graaf, I. A. M., & Groothuis, G. M. M. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011148 · Cited by 100 · see citing works

Phase II Metabolism of Hesperetin by Individual UDP-Glucuronosyltransferases and Sulfotransferases and Rat and Human Tissue Samples

Brand, W., Boersma, M. G., Bik, H., den Hil, E. F. H.-V., Vervoort, J. J. M., Barron, D., Meinl, W., Glatt, H. R., Williamson, G., van BLADEREN, P. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031047 · Cited by 99 · see citing works

A Comparison of Pharmacokinetics between Humans and Monkeys

Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028829 · Cited by 97 · see citing works

Structure and Concentration Changes Affect Characterization of UGT Isoform-Specific Metabolism of Isoflavones

Tang, L. Y., Singh, R., Liu, Z., & Hu, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002557 · Cited by 95 · see citing works

Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics

Ritter, J. K. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.1.93 · Cited by 95 · see citing works

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

Lee, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129068 · Cited by 93 · see citing works

CHARACTERIZATION OF MOUSE SMALL INTESTINAL CYTOCHROME P450 EXPRESSION

Zhang, Q., Dunbar, D., & Kaminsky, L. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1346 · Cited by 92 · see citing works

The Intestinal First-pass Metabolism of Substrates of CYP3A4 and P-glycoprotei—Quantitative Analysis Based on Information from the Literature

Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., et al. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.365 · Cited by 91 · see citing works

Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique

von Richter, O., Greiner, B., Fromm, M. F., FRASER, R., Omari, T. I., Barclay, M. L., Dent, J., Somogyi, A. A., & Eichelbaum, M. F. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117937 · Cited by 91 · see citing works

N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.

Schmider, J., Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., & Shader, R. I. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12105-8 · Cited by 89 · see citing works

Species Differences in In Vitro and In Vivo Small Intestinal Metabolism of CYP3A Substrates

Komura, H., & Iwaki, M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21121 · Cited by 88 · see citing works

Species Differences in UDP-Glucuronosyltransferase Activities in Mice and Rats

Shiratani, H., Katoh, M., Nakajima, M., & Yokoi, T. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021469 · Cited by 86 · see citing works

Effects of grapefruit juice on the pharmacokinetics of sildenafil

Jetter, A., Kinzig‐Schippers, M., Walchner‐Bonjean, M., Hering, U., Bulitta, J. B., Schreiner, P., Sörgel, F., & Fuhr, U. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121236 · Cited by 85 · see citing works

Effects of Continuous Ingestion of Green Tea or Grape Seed Extracts on the Pharmacokinetics of Midazolam

Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I., Nakamura, H., Nakasa, H., Ida, M., Nakamura, H., Kimura, N., Kimura, M., et al. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.280 · Cited by 84 · see citing works

Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10

Watanabe, Y., Nakajima, M., & Yokoi, T. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1462 · Cited by 82 · see citing works

Cytochrome P450 3A expression and activity in the human small intestine

YANG, J., Tucker, G. T., & Rostami‐Hodjegan, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.001 · Cited by 79 · see citing works

Extrahepatic metabolism of morphine occurs in humans

Mazoit, J., Sandouk, P., Scherrmann, J., & Roche, A. J. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.203 · Cited by 78 · see citing works

EXPRESSION PROFILES OF DRUG-METABOLIZING ENZYME CYP3A AND DRUG EFFLUX TRANSPORTER MULTIDRUG RESISTANCE 1 SUBFAMILY mRNAS IN RAT SMALL INTESTINE

Takara, K., Ohnishi, N., Horibe, S., & Yokoyama, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1235 · Cited by 78 · see citing works

The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)‐verapamil in humans

Sandström, R., Knutson, T. W., Knutson, L., Jansson, B., & Lennernäs, H. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00999.x · Cited by 77 · see citing works

In Vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance

Strelevitz, T. J., Foti, R., & Fisher, M. B. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20538 · Cited by 75 · see citing works

Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber

Lampen, A., Christians, U., Gonschior, A. K., Bader, A., Hackbarth, I., Engelhardt, W. V., & Sewing, K. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15346.x · Cited by 74 · see citing works

Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes

Yamanaka, H., Nakajima, M., Katoh, M., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016097 · Cited by 71 · see citing works

Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic Activities

Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016402 · Cited by 71 · see citing works

Effects of Intestinal and Hepatic Metabolism on the Bioavailability of Tacrolimus in Rats

Hashimoto, Y., Sasa, H., Shimomura, M., & Inui, K.-I. (1998) · Pharmaceutical Research · doi:10.1023/a:1011967519752 · Cited by 70 · see citing works

Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms

Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro, S., Sakaki, T., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014191 · Cited by 69 · see citing works

Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations

Gertz, M., Davis, J. D., Harrison, A. C., Houston, J. B., & Galetin, A. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049276 · Cited by 68 · see citing works

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

Masica, A. L., Mayo, G., & Wilkinson, G. R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.003 · Cited by 66 · see citing works

Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam

van Waterschoot, R. A. B., Rooswinkel, R. W., Sparidans, R. W., van Herwaarden, A. E., Beijnen, J. H., & Schinkel, A. H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029397 · Cited by 66 · see citing works

Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes

Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, T., Nakajima, M., & Yokoi, T. (2000) · Xenobiotica · doi:10.1080/00498250050200104 · Cited by 65 · see citing works

Isolation, Heterologous Expression and Functional Characterization of a Novel Cytochrome P450 3A Enzyme from a Canine Liver cDNA Library

Fraser, D. J., Feyereisen, R., Harlow, G. R., & Halpert, J. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37146-0 · Cited by 62 · see citing works

Drug Interactions and Interindividual Variability of Ciclosporin Metabolism in the Small Intestine

Lampen, A., Christians, U., Bader, A., Hackbarth, I., & Sewing, K. (2008) · Pharmacology · doi:10.1159/000139380 · Cited by 60 · see citing works

Pharmacokinetics of sildenafil after intravenous and oral administration in rats: Hepatic and intestinal first-pass effects

SHIN, H., Bae, S., & LEE, M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.04.005 · Cited by 60 · see citing works

Predicting Drug – Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein

Tachibana, T., Kato, M., Takano, J., & Sugiyama, Y. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328922 · Cited by 59 · see citing works

Cynomolgus monkey CYPs: a comparison with human CYPs

Iwasaki, K., & Uno, Y. (2009) · Xenobiotica · doi:10.1080/00498250903003135 · Cited by 58 · see citing works

Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes

Carr, B., Norcross, R., Fang, Y., Lu, P., Rodrigues, A. D., Shou, M., Rushmore, T. H., & Booth-Genthe, C. L. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009977 · Cited by 58 · see citing works

The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans

Takahashi, M., Washio, T., Suzuki, N., Igeta, K., & Yamashita, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21708 · Cited by 57 · see citing works

Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical.

Lown, K. S., Ghosh, M., & Watkins, P. B. (1998) · PubMed · Cited by 56 · see citing works

A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies

de Kanter, R., Tuin, A., van de Kerkhof, E. G., Martignoni, M., Draaisma, A. L., de Jager, M. H., de Graaf, I. A. M., Meijer, D. K. F., & Groothuis, G. M. M. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2004.07.007 · Cited by 55 · see citing works

Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques

Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., Fukuzaki, K., Utoh, M., Murayamay, N., & Yamazaki, H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029710 · Cited by 55 · see citing works

Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys

Ogasawara, A., Kume, T., & Kazama, E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011288 · Cited by 55 · see citing works

How important is intestinal cytochrome P450 3A metabolism?

van Herwaarden, A. E., van Waterschoot, R. A. B., & Schinkel, A. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.02.003 · Cited by 54 · see citing works

Dopamine Is a Low-Affinity and High-Specificity Substrate for the Human UDP-Glucuronosyltransferase 1A10

Itäaho, K., Court, M. H., Uutela, P., Kostiainen, R. K., Radominska-p, A., & Finel, M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025692 · Cited by 54 · see citing works

Erythromycin enhances the absorption of cyclosporin.

Gupta, S. K., Bakran, A., Johnson, R. W. G., & Rowland, M. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03320.x · Cited by 53 · see citing works

An Intestinal Epithelium-Specific Cytochrome P450 (P450) Reductase-Knockout Mouse Model: Direct Evidence for a Role of Intestinal P450s in First-Pass Clearance of Oral Nifedipine

Zhang, Q., Fang, C., Zhang, J., Dunbar, D. A., Kaminsky, L. S., & Ding, X. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025429 · Cited by 50 · see citing works

Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes

Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T., & Yokoi, T. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21830 · Cited by 48 · see citing works

Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation

Doherty, M. M., & Pang, K. S. (2000) · Pharmaceutical Research · doi:10.1023/a:1007548905772 · Cited by 46 · see citing works

EMPIRICAL VALIDATION OF A RAT IN VITRO ORGAN SLICE MODEL AS A TOOL FOR IN VIVO CLEARANCE PREDICTION

de Graaf, I. A. M., de Kanter, R., de Jager, M. H., Camacho, R., Langenkamp, E., van de Kerkhof, E. G., & Groothuis, G. M. M. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006726 · Cited by 45 · see citing works

Determination of baicalin and baicalein in rat plasma by high-performance liquid chromatography with electrochemical detection

Wakui, Y., Yanagisawa, E., Ishibashi, E., Matsuzaki, Y., Takeda, S., Sasaki, H., Aburada, M., & Oyama, T. (1992) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(92)80513-p · Cited by 43 · see citing works

Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys

Lindstrom, T. D., Whitaker, N. G., & Whitaker, G. W. (1984) · Xenobiotica · doi:10.3109/00498258409151482 · Cited by 43 · see citing works

Dose-dependent Intestinal and Hepatic First-pass Metabolism of Midazolam, a Cytochrome P450 3A Substrate with Differently Modulated Enzyme Activity in Rats

Higashikawa, F., Murakami, T., Kaneda, T., Kato, A., & Takano, M. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991771971 · Cited by 43 · see citing works

Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug–drug interaction model rats

Kanazu, T., Okamura, N., Yamaguchi, Y., Baba, T., & Koike, M. (2005) · Xenobiotica · doi:10.1080/00498250500093786 · Cited by 43 · see citing works

Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins.

Murakami, T., Nakanishi, M., Yoshimori, T., Okamura, N., Norikura, R., & Mizojiri, K. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.252 · Cited by 41 · see citing works

Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine

Zhang, Q.-Y., Kaminsky, L. S., Dunbar, D. A., Zhang, J., & Ding, X. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016543 · Cited by 40 · see citing works

Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey

Nishimura, T., Amano, N., Kubo, Y., Ono, M., Kato, Y., Fujita, H., Kimura, Y., & Tsuji, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013037 · Cited by 40 · see citing works

Localization and characterization of drugmetabolizing enzymes along the villus-crypt surface of the rat small intestine—I

Dubey, R. K., & Singh, J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90714-9 · Cited by 39 · see citing works

DEMONSTRATION OF DOCOSAHEXAENOIC ACID AS A BIOAVAILABILITY ENHANCER FOR CYP3A SUBSTRATES: IN VITRO AND IN VIVO EVIDENCE USING CYCLOSPORIN IN RATS

Hirunpanich, V., Katagi, J., Sethabouppha, B., & Sato, H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007088 · Cited by 39 · see citing works

Transfer of human artificial chromosome vectors into stem cells

Oshimura, M., & Katoh, M. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60557-3 · Cited by 39 · see citing works

Decreased Oral Absorption of Cyclosporine A after Liver Ischemia-Reperfusion Injury in Rats: The Contribution of CYP3A and P-Glycoprotein to the First-Pass Metabolism in Intestinal Epithelial Cells

Ikemura, K., Urano, K., Matsuda, H., Mizutani, H., Iwamoto, T., & Okuda, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145581 · Cited by 38 · see citing works

Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes

Takemoto, K., Yamazaki, H., Tanaka, Y., Nakajima, M., & Yokoi, T. (2003) · Xenobiotica · doi:10.1080/0049825021000022348 · Cited by 37 · see citing works

Tissue-Specific mRNA Expression Profiles of Drug-Metabolizing Enzymes and Transporters in the Cynomolgus Monkey

Nishimura, M., Koeda, A., Morikawa, H., Satoh, T., Narimatsu, S., & Naito, S. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.139 · Cited by 34 · see citing works

Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans

Kanazu, T., Yamaguchi, Y., Okamura, N., Baba, T., & Koike, M. (2004) · Xenobiotica · doi:10.1080/00498250410001685755 · Cited by 34 · see citing works

The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs.

Arellano, C., Philibert, C., Vachoux, C., Woodley, J. F., & Houin, G. (2007) · PubMed · Cited by 31 · see citing works

Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse

Zhu, Y., D’Agostino, J., & Zhang, Q.-Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037861 · Cited by 31 · see citing works

Poor Correlation Between Intestinal and Hepatic Metabolic Rates of CYP3A4 Substrates in Rats

Aiba, T., Takehara, Y., Okuno, M., & Hashimoto, Y. (2003) · Pharmaceutical Research · doi:10.1023/a:1023429401738 · Cited by 30 · see citing works

Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans

Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A. A., Eichelbaum, M. F., & Fromm, M. F. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.013 · Cited by 30 · see citing works

Regional Distribution of Cytochrome P450 mRNA Expression in the Liver and Small Intestine of Cynomolgus Monkeys

Nakanishi, Y., Matsushita, A., Matsuno, K., Iwasaki, K., Utoh, M., Nakamura, C., & Uno, Y. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.290 · Cited by 30 · see citing works

Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs

Kyokawa, Y., Nishibe, Y., Wakabayashi, M., Harauchi, T., Maruyama, T., Baba, T., & Ohno, K. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00164-8 · Cited by 30 · see citing works

Human UDP-glucuronosyltransferase, UGT1A8, glucuronidates dihydrotestosterone to a monoglucuronide and further to a structurally novel diglucuronide

Murai, T., Samata, N., Iwabuchi, H., & Ikeda, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009621 · Cited by 30 · see citing works

Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys

Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M., & Komuro, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034561 · Cited by 30 · see citing works

Metabolism of MK-0524, a Prostaglandin D2 Receptor 1 Antagonist, in Microsomes and Hepatocytes from Preclinical Species and Humans

Dean, B. J., Chang, S., Elipe, M. V. S., Xia, Y., Braun, M., Soli, E. D., Zhao, Y., Franklin, R. B., & Karanam, B. V. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011551 · Cited by 30 · see citing works

Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys

Ohtsuka, T., Yoshikawa, T., Kozakai, K., Tsuneto, Y., Uno, Y., Utoh, M., Yamazaki, H., & Kume, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032656 · Cited by 29 · see citing works

Differential expression ofCYP3A12andCYP3A26mRNAs in canine liver and intestine

Mealey, K. L., Jabbes, M., Spencer, E. S., & Akey, J. M. (2008) · Xenobiotica · doi:10.1080/00498250802446146 · Cited by 28 · see citing works

Metabolic Extraction of Nifedipine during Absorption from the Rat Small Intestine

Iwao, T., Inoue, K., Hayashi, Y., Yuasa, H., & Watanabe, J. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.546 · Cited by 28 · see citing works

Effects of 5-Fluorouracil on the Drug-Metabolizing Enzymes of the Small Intestine and the Consequent Drug Interaction with Nifedipine in Rats

Yoshisue, K., Nagayama, S., Shindo, T., & KAWAGUCHI, Y. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29647-6 · Cited by 28 · see citing works

Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat

Eeckhoudt, S., Horsmans, Y., & Verbeeck, R. K. (2002) · Xenobiotica · doi:10.1080/0049825021000012655 · Cited by 28 · see citing works

Effect of Oral Ketoconazole on First‐pass Effect of Nifedipine After Oral Administration in Dogs

Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W. F., Shimoda, M., & KOKUE, E. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10086 · Cited by 27 · see citing works

Stereoselective First-Pass Metabolism of Verapamil in the Small Intestine and Liver in Rats

Hanada, K., Ikemi, Y., Kukita, K., Mihara, K., & Ogata, H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020339 · Cited by 27 · see citing works

Species Difference in Nisoldipine Oxidation Activity in the Small Intestine

Komura, H., Yasuda, M., Yoshida, N. H., & Sugiyama, Y. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.427 · Cited by 27 · see citing works

Ethynylestradiol-Mediated Induction of Hepatic CYP3A9 in Female Rats: Implication for Cyclosporine Metabolism

Jäger, W. R., Correia, M. A., Bornheim, L. M., Mahnke, A., Hanstein, W. G., Xue, L., & Benet, L. Z. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14963-x · Cited by 27 · see citing works

Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine—II

Dubey, R. K., & Singh, J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90715-0 · Cited by 27 · see citing works

Comparison of Cytochrome P450 3A Enzymes in Cynomolgus Monkeys and Humans

Iwasaki, K., Murayama, N., Koizumi, R., Uno, Y., & Yamazaki, H. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-nt-022 · Cited by 26 · see citing works

The use of chromosome-based vectors for animal transgenesis

Kuroiwa, Y., Yoshida, H., Ohshima, T., Shinohara, T., Ohguma, A., Kazuki, Y., Oshimura, M., Ishida, I., & Tomizuka, K. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301754 · Cited by 26 · see citing works

Effects of St. John's wort extract on indinavir pharmacokinetics in rats: Differentiation of intestinal and hepatic impacts

Ho, Y., Huang, D.-K., Hsueh, W.-C., Lai, M.-Y., Yu, H., & Tsai, T. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.008 · Cited by 25 · see citing works

REGIOSELECTIVE GLUCURONIDATION OF DENOPAMINE: MARKED SPECIES DIFFERENCES AND IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ISOFORM

Kaji, H., & Kume, T. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002667 · Cited by 25 · see citing works

Cooperativity ofα-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human

Emoto, C., Yamazaki, H., Iketaki, H., Yamasaki, S., Satoh, T., Shimizu, R. W., Suzuki, S., Shimada, N., Nakajima, M., & Yokoi, T. (2001) · Xenobiotica · doi:10.1080/00498250110052120 · Cited by 25 · see citing works

Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activitiesin vitro

Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., & Yokoi, T. (2000) · Xenobiotica · doi:10.1080/00498250050200122 · Cited by 25 · see citing works

Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

Loureiro, A. I., Bonifácio, M. J., Fernandes‐Lopes, C., Almeida, L., Wright, L. C., & Soares-da-Silva, P. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010447 · Cited by 25 · see citing works

Pharmacokinetics of DA-7867, a New Oxazolidinone, after Intravenous or Oral Administration to Rats: Intestinal First-Pass Effect

Bae, S. K., Chung, W., Kim, E. J., Rhee, J. K., Kwon, J. W., Kim, W. B., & Lee, M. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.659-662.2004 · Cited by 24 · see citing works

Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans

Sakuda, S., Akabane, T., & Teramura, T. (2006) · Xenobiotica · doi:10.1080/00498250600571749 · Cited by 23 · see citing works

Effect of Lactobacillus casei on the Absorption of Nifedipine from Rat Small Intestine

Kato, R., Yuasa, H., Inoue, K., Iwao, T., Tanaka, K., Ooi, K., & Hayashi, Y. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.96 · Cited by 22 · see citing works

Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: In vitro and in vivo studies in rats

Hirunpanich, V., Murakoso, K., & Sato, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.09.037 · Cited by 22 · see citing works

Pharmacokinetics of Amitriptyline and One of Its Metabolites, Nortriptyline, in Rats: Little Contribution of Considerable Hepatic First-Pass Effect to Low Bioavailability of Amitriptyline Due to Great Intestinal First-Pass Effect

Bae, S. K., Yang, K., Aryal, D. K., Kim, Y. G., & Lee, M. G. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21511 · Cited by 22 · see citing works

Differentiation of Gut and Hepatic First-Pass Effect of Drugs: 1. Studies of Verapamil in Ported Dogs

Lee, Y.-H., Perry, B. A., Lee, H., Kunta, J. R., Sutyak, J. P., & Sinko, P. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013374630274 · Cited by 18 · see citing works

Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice

Kuze, J., Mutoh, T., Takenaka, T., Morisaki, K., Nakura, H., Hanioka, N., & Narimatsu, S. (2009) · Xenobiotica · doi:10.3109/00498250903215382 · Cited by 17 · see citing works

Characterization of Rat Intestinal Microsomal UDP-Glucuronosyltransferase Activity toward Mycophenolic Acid

Miles, K. K., Kessler, F. K., Smith, P. C., & Ritter, J. K. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010140 · Cited by 15 · see citing works

Effect of bile and lipids on the stereoselective metabolism of halofantrine by rat everted‐intestinal sacs

Patel, J. P., Korashy, H. M., El‐Kadi, A. O. S., & Brocks, D. R. (2009) · Chirality · doi:10.1002/chir.20740 · Cited by 14 · see citing works

Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone

Jin, M., Shimada, T., Yokogawa, K., Nomura, M., Kato, Y., Tsuji, A., & Miyamoto, K. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.11.015 · Cited by 13 · see citing works

Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats

Yokomasu, A., Yano, I., Sato, E., Masuda, S., Katsura, T., & Inui, K. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.469 · Cited by 12 · see citing works

Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats

Kurosawa, S., Uchida, S., Ito, Y., & Yamada, S. (2009) · Xenobiotica · doi:10.1080/00498250802621680 · Cited by 12 · see citing works

Presystemic elimination of morphine in anesthetized rabbits. Contribution of the intestine, liver, and lungs.

Abdallah, C., Besner, J., & du Souich, P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06624-3 · Cited by 8 · see citing works

Inhibition of Nifedipine Metabolism in Dogs by Erythromycin: Difference between the Gut Wall and the Liver

Tsuruta, S., Nakamura, K., Arimori, K., & Nakano, M. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06071.x · Cited by 6 · see citing works

Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT1A1,1A3 and 1A8

Syed, M., Basha, S. J. S., Shashikumar, D., Mullangi, R., & Srinivas, N. R. (2006) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190471 · Cited by 4 · see citing works

Pregnancy Does Not Increase CYP3A or P-Glycoprotein Activity in the Non-Human Primate, Macaca nemestrina

Zhang, H., Wu, X., Naraharisetti, S. B., Chung, F., Whittington, D., Mirfazaelian, A., & Unadkat, J. D. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153569 · Cited by 4 · see citing works

In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects

Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M. E., Brouwers, J., Flanagan, T. R., Harwood, M. D., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279 · see citing works

Duodenum Intestine-Chip for preclinical drug assessment in a human relevant model

Kasendra, M. J., Luc, R., Yin, J., Manatakis, D. V., Kulkarni, G., Lucchesi, C., Sliz, J. D., Apostolou, A. P., Sunuwar, L., Obrigewitch, J., et al. (2020) · eLife · doi:10.7554/elife.50135 · Cited by 227 · see citing works

An analysis of the use of animal models in predicting human toxicology and drug safety

Bailey, J., Thew, M., & Balls, M. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200306 · Cited by 182 · see citing works

Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects

Cherniakov, I., Domb, A. J., & Hoffman, A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999038 · Cited by 182 · see citing works

An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers

Xu, Y., Shrestha, N., Véronique Préat, A., & Beloqui, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.005 · Cited by 183 · see citing works

An update on the role of intestinal cytochrome P450 enzymes in drug disposition

Xie, F., Ding, X., & Zhang, Q.-Y. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.012 · Cited by 153 · see citing works

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · see citing works

Multiple NSAID-Induced Hits Injure the Small Intestine: Underlying Mechanisms and Novel Strategies

Boelsterli, U. A., Redinbo, M. R., & Saitta, K. S. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs310 · Cited by 142 · see citing works

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades

Davies, M., Jones, R. D. O., Grime, K., Jansson-Löfmark, R., Fretland, A. J., Winiwarter, S., Morgan, P., & McGinnity, D. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.004 · Cited by 123 · see citing works

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

Peters, S. A., Jones, C. R., Ungell, A.-L. B., & Hatley, O. J. D. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0351-6 · Cited by 105 · see citing works

Pre-systemic metabolism of orally administered drugs and strategies to overcome it

de Sousa, I. P., & Bernkop‐Schnürch, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.004 · Cited by 90 · see citing works

Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications

Neal-Kluever, A., Fisher, J. W., GRYLACK, L. J., Kakiuchi-Kiyota, S., & Halpern, W. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084418 · Cited by 90 · see citing works

Human Microphysiological Models of Intestinal Tissue and Gut Microbiome

Steinway, S. N., Saleh, J., Koo, B., Delacour, D., & Kim, D. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00725 · Cited by 79 · see citing works

Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective and Efficient Prediction of Human Pharmacokinetics

Grime, K., Barton, P., & McGinnity, D. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 78 · see citing works

Role of vitamin D receptor in the regulation of CYP3A gene expression

Qin, X., & Wang, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.005 · Cited by 74 · see citing works

Lipid-Metabolizing CYPs in the Regulation and Dysregulation of Metabolism

Bishop‐Bailey, D., Thomson, S. J. P., Askari, A., Faulkner, A., & Wheeler-Jones, C. P. D. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071813-105747 · Cited by 64 · see citing works

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

Jones, C. R., Hatley, O. J. D., Ungell, A.-L. B., Hilgendorf, C., Peters, S. A., & Rostami‐Hodjegan, A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9889-y · Cited by 61 · see citing works

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Chessari, G., Hardcastle, I. R., Ahn, J. S., Anil, B., Anscombe, E., Bawn, R. H., Bevan, L., Blackburn, T. J., Buck, I. M., Cano, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02188 · Cited by 58 · see citing works

Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients

Sayama, H., Takubo, H., Komura, H., Kogayu, M., & Iwaki, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9626-3 · Cited by 56 · see citing works

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H ,2 H ,3 H -pyrrolo[3,2- b ]pyridin-1-yl)-2-[(2 R ,5 R )-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)

Johnson, C. N., Ahn, J. S., Buck, I. M., Chiarparin, E., Day, J. E. H., Hopkins, A., Howard, S., Lewis, E. J., Martins, V., Millemaggi, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00900 · Cited by 53 · see citing works

Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development

Karlsson, F. H., Bouchène, S., Hilgendorf, C., Dolgos, H., & Peters, S. A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.051664 · Cited by 45 · see citing works

Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties

Murakami, T., Bodor, E., & Bodor, N. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2203857 · Cited by 41 · see citing works

Transcriptome comparisons of in vitro intestinal epithelia grown under static and microfluidic gut-on-chip conditions with in vivo human epithelia

Kulthong, K., Hooiveld, G. J. E. J., Duivenvoorde, L. P. M., Estruch, I. M., Marin, V., van der Zande, M., & Bouwmeester, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-82853-6 · Cited by 40 · see citing works

A comparative evaluation of models to predict human intestinal metabolism from nonclinical data

Yau, E., Petersson, C., Dolgos, H., & Peters, S. A. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2068 · Cited by 37 · see citing works

Stable Isotope-Assisted Metabolomics for Deciphering Xenobiotic Metabolism in Mammalian Cell Culture

Flasch, M., Bueschl, C., Woelflingseder, L., Schwartz, H., Adam, G., Schuhmacher, R., Marko, D., & Warth, B. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b01016 · Cited by 35 · see citing works

Prediction of hepatic and intestinal glucuronidation using in vitro–in vivo extrapolation

Naritomi, Y., Nakamori, F., Furukawa, T. Y., & Tabata, K. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.10.001 · Cited by 34 · see citing works

Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys

Furukawa, T. Y., Naritomi, Y., Tetsuka, K., Nakamori, F., Moriguchi, H., Yamano, K., Terashita, S., Tabata, K., & Teramura, T. (2013) · Xenobiotica · doi:10.3109/00498254.2013.828362 · Cited by 31 · see citing works

In VivoandIn VitroMetabolites from the Main Diester and Monoester Diterpenoid Alkaloids in a Traditional Chinese Herb, theAconitumSpecies

Zhang, M., Peng, C., & Li, X. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/252434 · Cited by 31 · see citing works

Advances in reconstructing intestinal functionalities in vitro: From two/three dimensional-cell culture platforms to human intestine-on-a-chip

Wang, L., Wu, J., Chen, J., Dou, W., Zhao, Q., Han, J., Liu, J., Su, W., Li, A., Liu, P., et al. (2021) · Talanta · doi:10.1016/j.talanta.2021.122097 · Cited by 28 · see citing works

An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

Alqahtani, S., Bukhari, I. A., Albassam, A. A., & Alenazi, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482277 · Cited by 28 · see citing works

Targeted Screen for Human UDP-Glucuronosyltransferases Inhibitors and the Evaluation of Potential Drug-Drug Interactions with Zafirlukast

Oda, S., Fujiwara, R., Kutsuno, Y., Fukami, T., Itoh, T., Yokoi, T., & Nakajima, M. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062141 · Cited by 27 · see citing works

Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats

Qin, X., Lu, J., Wang, P., Xu, P., Liu, M., & Wang, X. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.013 · Cited by 26 · see citing works

Human intestine and liver microsomal metabolic differences between C19-diester and monoester diterpenoid alkaloids from the roots of Aconitum carmichaelii Debx.

Zhang, M., Peng, C., & Li, X. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.09.011 · Cited by 22 · see citing works

Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice

Wang, H., Zhang, J., Zhang, X., Zhao, N., Zhou, Z., Tao, L., Fu, L., Peng, S., & Chai, J. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166556 · Cited by 20 · see citing works

A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects

Sun, L., McDonnell, D., Yu, M., Kumar, V., & Moltke, L. L. V. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00775-8 · Cited by 20 · see citing works

NANOTECHNOLOGY APPROACH-SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS)

Annisa, R., Mutiah, R., Yuwono, M., & Hendradi, E. (2023) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2023v15i4.47644 · Cited by 17 · see citing works

Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors

Liu, S. N., Lu, J. B. L., Watson, C. J. W., Lazarus, P. J., Desta, Z., & Gufford, B. T. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085035 · Cited by 17 · see citing works

Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

Bueters, T., Juric, S., Sohlenius-Sternbeck, A.-K., Hu, Y., & Bylund, J. (2013) · Xenobiotica · doi:10.3109/00498254.2012.752117 · Cited by 16 · see citing works

Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal–systemic concentration difference method

Kadono, K., Koakutsu, A., Naritomi, Y., Terashita, S., Tabata, K., & Teramura, T. (2013) · Xenobiotica · doi:10.3109/00498254.2013.869375 · Cited by 15 · see citing works

Identification of gut‐derived metabolites of maslinic acid, a bioactive compound from Olea europaea L

Lozano‐Mena, G., Sánchez‐González, M., Parra, A., Juan, M. E., & Planas, J. M. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201501060 · Cited by 15 · see citing works

Glucuronidation as a metabolic barrier against zearalenone in rat everted intestine

Ieko, T., Inoue, S., INOMATA, Y., Inoue, H., Fujiki, J., & Iwano, H. (2019) · Journal of Veterinary Medical Science · doi:10.1292/jvms.19-0570 · Cited by 14 · see citing works

Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans

Li, X., Sun, J.-C., Guo, Z., Zhong, D., & Chen, X. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085092 · Cited by 13 · see citing works

Induction by Phenobarbital of Phase I and II Xenobiotic-Metabolizing Enzymes in Bovine Liver: An Overall Catalytic and Immunochemical Characterization

Cantiello, M., Carletti, M., Giantin, M., Gardini, G., Capolongo, F., Cascio, P., Pauletto, M., Girolami, F., Dacasto, M., & Nebbia, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073564 · Cited by 13 · see citing works

Exploration of the hepatoprotective chemical base of an orally administered herbal formulation (YCHT) in normal and CCl4-intoxicated liver injury rats. Part 1: Metabolic profiles from the liver-centric perspective

Liu, H., Chen, M., Yin, H., Hu, P., Wang, Y., Liu, F., Tian, X., & Huang, C. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.03.044 · Cited by 13 · see citing works

Relationship between low midazolam metabolism by cytochrome P450 3A in mice and the high incidence of birth defects

Kitaoka, S., Hatogai, J., Iimura, R., Yamamoto, Y., Oba, K., Nakai, M., Kusunoki, Y., Ochiai, W., & Sugiyama, K. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.65 · Cited by 11 · see citing works

Presystemic Metabolism of AZ’0908, A Novel mPGES-1 Inhibitor: An In Vitro and In Vivo Cross-Species Comparison

Bylund, J., & Bueters, T. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23443 · Cited by 10 · see citing works

Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application ofmdr1aknockout (−/−) rats into absorption study of multiple transporter substrate

Suzuki, M., Komura, H., Yoshikawa, T., Enya, S., Nagao, A., Takubo, H., & Kogayu, M. (2014) · Xenobiotica · doi:10.3109/00498254.2014.920551 · Cited by 10 · see citing works

ADME Optimization in Drug Discovery

McGinnity, D. F., & Grime, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12365-0 · Cited by 9 · see citing works

Identification of human UDP-glucuronosyltransferase isoforms involved in the isofraxidin glucuronidation and assessment of the species differences of the reaction

Meng, F., Li, Y., He, G.-Y., Ge, G., & Liu, S. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.11.017 · Cited by 9 · see citing works

Autoinduction of phase I and phase II metabolism of artemisinin in rats

Xing, J., Du, F., Liu, T., & Zhu, F. (2012) · Xenobiotica · doi:10.3109/00498254.2012.669871 · Cited by 7 · see citing works

Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first‐pass removal in rats

Noh, K., Chen, S., Yang, Q. J., & Pang, K. S. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2051 · Cited by 7 · see citing works

Oral bioavailability enhancement of chrysin using a spray-dried solid dispersion formulation with sodium dodecyl sulfate and polyvinylpyrrolidone

Pang, M., Lee, J., Lee, J.-G., Jeon, J.-H., Choi, M., & Song, I. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00744-8 · Cited by 7 · see citing works

ADME Optimization in Drug Discovery

McGinnity, D. F., & Grime, K. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00298 · Cited by 6 · see citing works

Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

Burger, D. M., Brake, L. H. M. T., & Aarnoutse, R. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-72422-5_2 · Cited by 6 · see citing works

Human Pluripotent Stem Cell-Derived Organoids as a Model of Intestinal Xenobiotic Metabolism

Sasaki, K., Inoue, M., Machida, M., Kawasaki, T., Tsuruta, S., Uchida, H., Sakamoto, S., Kasahara, M., Umezawa, A., & Akutsu, H. (2021) · StemJournal · doi:10.3233/stj-200001 · Cited by 6 · see citing works

Glucuronidation

Pan, Y. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016414-00278 · Cited by 5 · see citing works

In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs

Juvonen, R. O., Heikkinen, A. T., Kärkkäinen, O. K., Jehangir, R., Huuskonen, J., Troberg, J., Raunio, H., Pentikäinen, O. T., & Finel, M. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105118 · Cited by 5 · see citing works

Predictive Biopharmaceutics and Pharmacokinetics

Yang, Y., Zhao, Y., Duan, J. Z., Zhao, P., Zhao, L. Y., & Zhang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802447-8.00015-7 · Cited by 5 · see citing works

Microminipig: A suitable animal model to estimate oral absorption of sustained-release formulation in humans

Hamada, T., Watanabe, Y., Iida, K., Sano, N., & Amano, N. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119457 · Cited by 3 · see citing works

Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase

Ahmed, A. N., Rostami‐Hodjegan, A., Barber, J., & Al‐Majdoub, Z. M. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000813 · Cited by 3 · see citing works

The Rat

Johnson, M., Gad, S. C., & Kemper, C. J. (2015) · CRC Press eBooks · doi:10.1201/b18705-4 · Cited by 2 · see citing works

Chronopharmacokinetics and mechanisms of gefitinib in a nude mice model of non-small cell lung cancer

Wang, L., Li, L., Zhao, L., Liu, C., Liu, J., Liu, L., Lin, P., Liu, B., & Li, M. (2016) · RSC Advances · doi:10.1039/c6ra13854c · Cited by 2 · see citing works

Identification of Cannabidivarin Metabolites in Different Mouse Organs Using Ultra-Performance Liquid Chromatography Coupled to a Quadrupole Time-of-Flight Mass Spectrometer

Zhang, M., Bai, L., Yau, L., Tong, T., Zhang, W., & Jiang, Z. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0161 · Cited by 1 · see citing works

The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy

Martins, V., Ward, G. A., Smyth, T., Reader, M., Chessari, G., Johnson, C., & Wilsher, N. E. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70030 · Cited by 1 · see citing works

Characterization of In Vitro metabolic profiles of crepidatin in human liver microsomes and hepatocytes using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS

Sun, Y., Zhou, J., Hou, X. S., Ma, T., Qiao, Y., Sun, L., & Cheng, H. H. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117269 · Cited by 1 · see citing works

BMAL1-mediated transcriptional regulation of CYP3A13 drives circadian rhythms in intestinal first-pass metabolism

Wang, H., Xu, J., Xu, H., Lin, L., Huang, Y., Wu, B., Lu, D., Guo, L., & Dong, D. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117981 · Cited by 1 · see citing works

Role of CYP3A5 and CYP3A4 in the metabolism and toxicity of 10-hydroxyl mesaconitine, a new potential toxicity marker of Radix Aconiti Lateralis Preparata (Fuzi), in vitro and in vivo

Fu, Y., Cai, Y., Li, F., Ma, T., Wang, C., Zhang, R., Liu, Z., Bai, D., Liang, Q., & Zhu, L. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100352 · Cited by 1 · see citing works

Oral Anatomy and Physiology in the Companion Animal

Sutton, S. C. (2012) · Advances in delivery science and technology · doi:10.1007/978-1-4614-4439-8_4 · Cited by 1 · see citing works

Non-Cytochrome P450 Enzymes and Glucuronidation

Hutzler, J. M., & Zientek, M. A. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622376-00079 · Cited by 1 · see citing works

The Interplay Between Drug Release and Intestinal Gut‐Wall Metabolism

Darwich, A. S., Hatley, O. J. D., Olivares‐Morales, A., Salem, F., Margolskee, A., & Rostami‐Hodjegan, A. (2022) · doi:10.1002/9781119772729.ch4 · Cited by 1 · see citing works

Raloxifene for the Treatment of Triple Negative Breast Cancer

Dzeyk, J. (2012) · Otago University Research Archive (University of Otago)

CELL MODELS FOR STUDYING THE INTERPLAY BETWEEN CONJUGATIVE METABOLISM AND EFFLUX TRANSPORTERS: ESTABLISHING UGT1A1, UGT2B7 AND MRP3 TRANSFECTED MDCK CELL LINES

Järvinen, E. (2016) · Työväentutkimus Vuosikirja

Genetically Humanized Animal Models

Samuelsson, K., Scheer, N., Wilson, I. D., Wolf, C. R., & Henderson, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12376-5

Intestinal Epithelium and Drug Transporters

Ménochet, K., Chanteux, H., Henshall, J., Nicolas, J., Wright, S., van Asperen, J., & Ungell, A.-L. B. (2022) · doi:10.1002/9781119772729.ch3

Self nanoemulsifying drug delivery systems in colon targeting

Demiralp, B., Al-Mohaya, M., Çelik, Y. S., Güngör, S., & Özsoy, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24806-1.00025-x

Impact of Individual and Cassette Administration on Pharmacokinetics of Prednisolone, Diclofenac, and Methotrexate in a Rodent Model of Rheumatoid Arthritis

Kumar, S., Ravulapalli, S. Y., Singh, S., Gupta, S., & Srivastava, P. (2025) · Recent Advances in Inflammation & Allergy Drug Discovery · doi:10.2174/0127722708344359250414035502

Species differences in the hepatobiliary disposition of morphine-6-glucuronide mediated by hepatic transporters in rats and humans

Guo, Z., Wang, H., Xie, N., Zhou, Y., Zhang, M.-L., Kang, X.-Y., Wang, J., Zhu, Q., & Chen, X.-Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01658-9

Mechanical modulation of morphogenesis in the intestinal epithelium : from stem cell niche to terminal differentiation

Saleh, J. (2021) · doi:10.70675/088dc064z6d07z4b9ezab01zb558922b38ea

BindingDB Entry 50001905: A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one

BindingDB (2020) · UC San Diego · doi:10.7270/q2tt4thh

Species Differences in In Vitro and In Vivo Small Intestinal Metabolism of CYP3A Substrates

Komura, H., & Iwaki, M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21121 · Cited by 88 · see citing works

Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data — correlation with in in vivo data using mucosal blood flow

Klippert, P. J. M., Borm, P. J. A., & Noordhoek, J. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90068-5 · Cited by 38 · see citing works

Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal–systemic concentration difference method

Kadono, K., Koakutsu, A., Naritomi, Y., Terashita, S., Tabata, K., & Teramura, T. (2013) · Xenobiotica · doi:10.3109/00498254.2013.869375 · Cited by 15 · see citing works

Species Differences in Intestinal Metabolic Activities of Cytochrome P450 isoforms between Cynomolgus Monkeys and Humans

Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M., & Komuro, S. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-sh-119 · Cited by 28 · see citing works

In vitro and in vivo intestinal and hepatic oxidative metabolism of typical cytochrome P450 3A substrates, midazolam, nifedipine, and quinidine, in minipigs: a comparison with humans, monkeys, and dogs

Sakai, C., Higashi, E., Iwano, S., Miyamoto, Y., Yamazaki, H., & Uchida, M. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2711041 · Cited by 1 · see citing works